Cargando…

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?

Detalles Bibliográficos
Autores principales:	Chakraborty, Chiranjib, Bhattacharya, Manojit, Chopra, Hitesh, Islam, Md. Aminul, Saikumar, Gutulla, Dhama, Kuldeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132296/ https://www.ncbi.nlm.nih.gov/pubmed/36917125 http://dx.doi.org/10.1097/JS9.0000000000000246

Ejemplares similares

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
por: Faraone, Julia N., et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

Xbb subvariant of Omicron: Can the new wave sneak past your immune defense?
por: Hefnawy, Mahmoud T., et al.
Publicado: (2023)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

BF.7 Omicron subvariant (BA.5.2.1.7) posing fears of a rise in COVID-19 cases again: a critical appraisal and salient counteracting strategies
por: Dhama, Kuldeep, et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

What to know about Omicron XBB.1.5
por: Vogel, Lauren
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
por: John, Okesanya Olalekan, et al.
Publicado: (2023)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Recent update on XBB.1.5 emerging novel mutation of COVID-19
por: Amin, Ruhul, et al.
Publicado: (2023)

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
por: Parums, Dinah V.
Publicado: (2023)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
por: Yue, Can, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023)

Imprinted hybrid immunity against XBB reinfection
por: Boyton, Rosemary J, et al.
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
por: Ju, Bin, et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook – 2023
por: Akash, Shopnil, et al.
Publicado: (2023)

XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2
por: Popovic, Marko E.
Publicado: (2023)

Potential threat and possible global spread of the novel SARS-CoV-2 Omicron subvariants including XBB.1.16 during the Indian Premier League 2023: strict implementation of traveller guidelines suggested
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB
por: Wang, Yi, et al.
Publicado: (2023)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
por: Qu, Panke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_75e7u8h3a7pmcujevaqtinm91o